Q-omics provides the consensus-scored LINC01513 profile across patient tissues and cancer cell-line models. LINC01513 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC01513 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LINC01513 RNA expression shows 6,967 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, KIRC, and STAD as cancer lineages where LINC01513 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01513 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01513 survival associations across molecular data types. LINC01513 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01513 RNA expression–survival associations across cancer types. High LINC01513 expression shows unfavorable associations in ACC, LGG, ESCA and KIRP, but favorable associations in BRCA and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC01513 RNA expression.
This table summarizes LINC01513 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01513. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01513 shows lower tumor expression in LUSC, LUAD, KICH and BLCA and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher LINC01513 RNA expression in tumor versus normal tissue (log2 FC = +0.423, t-test p < 0.001).
This table shows molecular features associated with LINC01513 in patient tissues and cancer cell lines. In patient samples, LINC01513 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
